StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$148.36−1.16 (-0.78%)

Close on Nov 2, 2026Market cap $366.03BP/E 118.7Yield 2.21%

Merck Arcoxia by Quarter

Arcoxia (etoricoxib, legacy pre-Organon spin-off) — Worldwide sales ($M) ($M)

QuarterlyAnnual

Merck Arcoxia: $56M in Q1 2021, down 20.0% from a year earlier. No newer figure appears in the documents we track.

Latest, Q1 2021
56
Period ended Mar 31, 2021
Change on a year earlier
-20.0%
70 in Q1 2020
History
21 quarters
Since Q1 2016
Sources
5
Documents cited below

Where the Q1 2021 figure comes from

“|| Arcoxia | 56 | 70 | 65 | 68 | 54 | 258 | -20 | -22”

Source: Form 8-K (tm2114316d1_ex99-1.htm, filed 2021-04-29) ↗

Reported in Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedArcoxia (etoricoxib, legacy pre-Organon spin-off) — Worldwide sales ($M) ($M)Year on yearSource
Q1 2021Mar 31, 202156-20.0%Form 8-K (tm2114316d1_ex99-1.htm, filed 2021-04-29) ↗
Q4 2020Dec 31, 202054-19.4%Form 8-K (tm2114316d1_ex99-1.htm, filed 2021-04-29) ↗
Q3 2020Sep 30, 202068-5.6%Form 8-K (tm2114316d1_ex99-1.htm, filed 2021-04-29) ↗
Q2 2020Jun 30, 202065-13.3%Form 8-K (tm2114316d1_ex99-1.htm, filed 2021-04-29) ↗
Q1 2020Mar 31, 202070-6.7%Form 8-K (tm2114316d1_ex99-1.htm, filed 2021-04-29) ↗
Q4 2019Dec 31, 201967-22.1%Form 8-K (tm213179d2_ex99-1.htm, filed 2021-02-04) ↗
Q3 2019Sep 30, 201972-13.3%Form 8-K (tm213179d2_ex99-1.htm, filed 2021-02-04) ↗
Q2 2019Jun 30, 201975-10.7%Form 8-K (tm213179d2_ex99-1.htm, filed 2021-02-04) ↗
Q1 2019Mar 31, 201975-9.6%Form 8-K (tm213179d2_ex99-1.htm, filed 2021-02-04) ↗
Q4 2018Dec 31, 201886-5.5%Form 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗
Q3 2018Sep 30, 201883+3.8%Form 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗
Q2 2018Jun 30, 201884-5.6%Form 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗
Q1 2018Mar 31, 201883-19.4%Form 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗
Q4 2017Dec 31, 201791-15.7%Form 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗
Q3 2017Sep 30, 201780-29.8%Form 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗
Q2 2017Jun 30, 201789-23.9%Form 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗

Breakdown

What makes up arcoxia

Cite this data

StockData. (2026). Merck Arcoxia ($M), quarterly Q1 2016–Q1 2021 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-arcoxia

See every metric in the Merck KPI table. Data updated Oct 26, 2026.